SA 9.4 Can we de-escalate immunotherapy and chemotherapy in TNBC?

SA 9.4 Can we de-escalate immunotherapy and chemotherapy in TNBC?

Bibliographic Details
Main Author:	H. Bonnefoi
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623001066

Similar Items

SA 9.2 Optimal systemic therapy for residual disease in TNBC
by: S. Loibl
Published: (2023-03-01)

Editorial JVE 9.4
Published: (2023-12-01)

SA 7.4 De-escalation of axillary radiotherapy - the time has come!
by: I. Meattini
Published: (2023-03-01)

Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC
by: Haoming Wu, et al.
Published: (2023-03-01)

Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment
by: Yalan Yang, et al.
Published: (2024-10-01)

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
by: Thomas Karn, et al.
Published: (2020-10-01)

BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy
by: Sushmitha Sriramulu, et al.
Published: (2024-05-01)

Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse
by: Mohammed Ridha Moamin, et al.
Published: (2023-11-01)

High Intensity Focused Ultrasound‐Driven Nanomotor for Effective Ferroptosis‐Immunotherapy of TNBC
by: Xiangrong Yu, et al.
Published: (2024-04-01)

TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
by: Desh Deepak Singh, et al.
Published: (2021-07-01)

Review: Escalating immunotherapy of multiple sclerosis
by: Peter Rieckmann, et al.
Published: (2008-11-01)

5′-Oxospiro-(fluorene-9,4′-imidazolidine)-2′-thione
by: Dimitar Stoitsov, et al.
Published: (2024-08-01)

All minimal [9,4] 2 -codes are hyperbolic quadrics
by: Valentino Smaldore
Published: (2023-11-01)

Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy
by: Valérie Laurent-Matha, et al.
Published: (2025-01-01)

Functional mapping of sensorimotor activation in the human thalamus at 9.4 Tesla
by: Edyta Charyasz, et al.
Published: (2023-03-01)

Sleep fMRI with simultaneous electrophysiology at 9.4 T in male mice
by: Yalin Yu, et al.
Published: (2023-03-01)

A Photometric Redshift of z ~ 9.4 for GRB 090429B
by: Cucchiara, A, et al.
Published: (2011)

Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics
by: Shi-liang Chen, et al.
Published: (2025-01-01)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
by: Shipra Gandhi, et al.
Published: (2021-03-01)

PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
by: Yuanzhen Ma, et al.
Published: (2024-04-01)

The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?Research in context
by: Joan Martínez Vidal, et al.
Published: (2024-12-01)

A high-throughput eight-channel probe head for murine MRI at 9.4 T.
by: Lanz, T, et al.
Published: (2010)

Can we individualize chemotherapy for colorectal cancer?
by: Chan, R, et al.
Published: (2004)

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
by: Iris Y. Sheng, et al.
Published: (2019-01-01)

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
by: Seock-Ah Im, et al.
Published: (2024-09-01)

Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
by: Kuojun Ren, et al.
Published: (2024-10-01)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
by: Jiaxin Hong, et al.
Published: (2022-11-01)

Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy
by: Min Woo Kim, et al.
Published: (2024-02-01)

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach
by: Varduhi Petrosyan, et al.
Published: (2023-01-01)

SA 11.3 Can we omit adjuvant endocrine therapy?
by: F. Cardoso
Published: (2023-03-01)

Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma
by: Jacob M. Siewert, et al.
Published: (2023-11-01)

The therapeutic role of γδT cells in TNBC
by: Wenjing Li, et al.
Published: (2024-06-01)

Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy
by: Fangrui Zhao, et al.
Published: (2023-12-01)

Chleb żałoby (Oz 9,4) – praktyka żałobna czy znak jej zakończenia?
by: Janusz Lemański
Published: (2024-01-01)

Deterministic Tractography Analysis of Rat Brain Using SIGMA Atlas in 9.4T MRI
by: Sang-Jin Im, et al.
Published: (2021-12-01)

P9.4 COMPARISON OF DIFFERENT METHODS OF VASCULAR PHENOTYPING IN PATIENTS AT CARDIOVASCULAR RISK
by: C. Brown, et al.
Published: (2014-11-01)

Real de-escalation or escalation in disguise?
by: Maggie Banys-Paluchowski, et al.
Published: (2023-06-01)

Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment
by: Zhang Y, et al.
Published: (2023-07-01)

De-Escalation of Surgical Treatment after Neoadjuvant Chemotherapy in Breast Cancer Patients
by: Gianluca Franceschini, et al.
Published: (2024-05-01)

Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy
by: Georgina E. Wood, et al.
Published: (2023-10-01)